Supernus Pharmaceuticals : 2023 Annual Report : comparemela.

Dear Supernus Stockholder,


We are very pleased with our performance in 2023 as we continued to successfully transition from our mature brands and set the stage to...

Related Keywords

Washington , United States , Rockville , Maryland , Delaware , Jacka Khattar , , Stock Market , Shire Laboratories Inc , Takeda Pharmaceutical Company Ltd , Supernus Pharmaceuticals , Supernus Pharmaceuticals Inc , Nasdaq , Adamas Operations , Mdd Us Operations , Drug Administration , Securities Exchange , Exchange Commission , Shire Plc , Stock Exchange , Dear Supernus Stockholder , Novel Non Stimulant , Complete Response Letter , New Drug Application , Chief Executive Officer , West Avenue Rockville , Securities Exchange Act , Interactive Data File , Regulations T , Sarbanes Oxley Act , Proxy Statement , Annual Report , Year Ended December , For Registrant , Common Equity , Related Stockholder Matters , Equity Securities , Financial Condition , Qualitative Disclosures , Market Risk , Supplementary Data , Executive Officers , Corporate Governance , Certain Owners , Related Stockholder , Related Transactions , Director Independence , Accounting Fees , Financial Statement Schedules , Securities Act , New Drug Applications , Corporate Integrity Agreement , Shire Laboratories , Lennox Gastaut Syndrome , Itemi Business Intellectualproperty , Risk Factors Risksrelated , Standard Review , Investigational New Drug , Montgomery Asberg Depression Rating Scale , Total Score , Major Depressive Disorder , Hamilton Depression Rating , Orphan Drug , Dravet Syndrome , Markets ,